Immune Therapeutics welcomes
Kevin Phelps to Board of Directors
ORLANDO, FL
-- January 9, 2019 -- InvestorsHub NewsWire --
Immune
Therapeutics, Inc. (OTCQB:IMUN)
("Immune Therapeutics", "IMUN" or the "Company"), a late stage
clinical biopharmaceutical company focused on the development of
therapies for the treatment of autoimmune diseases, inflammatory
diseases, cancer and HIV/AIDS has announced today that Kevin
Phelps, CPA, has been appointed to its Board of
Directors.
Kevin Phelps is a finance and
business development professional who has spent his career
determining, satisfying and managing the operational needs of a
wide range of companies. With greater than 25 years of broad,
professional corporate experience, Mr. Phelps has held senior
management positions, successfully raising capital for startup
companies, managing financial organizations and developing new
businesses through technology, strategic alliances and acquisition
projects.
Mr. Phelps is a General
Partner in Trillium Group, LLC, a Rochester, New York based
venture capital firm and a Founder of Cashel Rock Advisors
and FinanciaLink
Strategic
Alliances, two private wealth management firms specializing in
strategies for corporations and high net-worth
individuals.
His professional experience
began as a CPA with Price Waterhouse (now PwC), where he consulted
with over 20 companies with a principal focus on emerging growth
opportunities. In 1987, he was recruited to head financial planning
for Eastman Kodak's BioProducts
Division. He
assisted in the spinoff of the business into an international joint
venture and became the Chief Financial Officer of the new
entity, Genencor International, Inc. In this
role, he created and managed Genencor's
finance and
treasury groups and established the company's accounting and
reporting practices. He raised in excess of $100 million in debt
capital to fund Genencor's
operations and
expansion. He also served as Vice President of New Business
Development.
"We are very pleased to
welcome Mr. Phelps to our Board of Directors. His extensive
experience as a finance specialist, along with his deep knowledge
of business development and operations, will assist the company in
moving to the forefront of specialized pharmaceuticals," stated
Noreen Griffin, President and CEO of Immune Therapeutics,
Inc.
"I am excited to join Immune
Therapeutics' Board of Directors and to contribute my experience in
entrepreneurial ventures. Immune Therapeutics has great potential,
and I
intend to
assist in maximizing this potential to bring unprecedented ROI for
investors," said Mr. Phelps.
"I look forward to working
with Mr. Phelps. Mr. Phelps's proven leadership in business and
finance make him an excellent addition to IMUN's Board," stated Dr.
Roscoe Moore, Chairman of Immune Therapeutics' Board of Directors,
member of the company's Scientific Advisory Board, and Former
United States Assistant Surgeon General.
ABOUT IMMUNE THERAPEUTICS,
INC.
Immune Therapeutics Inc. is a
late stage clinical stage biopharmaceutical company focused on the
development and commercialization of our highly innovative
immunotherapies. IMUN is a biotechnology company developing
T-Activation immunotherapies to achieve immunomodulation in
patients with autoimmune and inflammatory diseases, cancer
and other
infectious
disease.
Forward-Looking
Statements
This release may contain
forward-looking statements. Actual results may differ from those
projected due to a number of risks and uncertainties, including,
but not limited to, the possibility that some or all the matters
and transactions considered by the Company may not proceed as
contemplated, and by all other matters specified in the Company's
filings with the Securities and Exchange Commission. These
statements are made based upon current expectations that are
subject to risk and uncertainty. The Company does not undertake to
update forward-looking statements in this news release to reflect
actual results, changes in assumptions or changes in other factors
affecting such forward-looking information. Assumptions and other
information that could cause results to differ from those set forth
in the forward-looking information can be found in the Company's
filings with the Securities and Exchange Commission (www.sec.gov), including its recent
periodic reports.
Contact:
888-613-8802
http://www.immunetherapeutics.com/